​

BeOne Medicines (ONC) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChartTranscripts

ONC Stock Forecast

BeOne Medicines (ONC) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $384.00, with a high of $385.00 and a low of $383.00. This represents a 21.74% increase from the last price of $315.43.

ONC Stock Rating

BeOne Medicines stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

ONC Price Target Upside V Benchmarks

TypeNameUpside
StockBeOne Medicines21.74%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts124
Avg Price Target$383.00$384.00$343.75
Last Closing Price$315.43$315.43$315.43
Upside/Downside21.42%21.74%8.98%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2581711-27
Sep, 2571711-26
Aug, 257151--23
Jul, 257151--23
Jun, 258141--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 20, 2025Sean LaamanMorgan Stanley$383.00$319.1919.99%21.42%
Sep 18, 2025Barclays$385.00$337.4314.10%22.06%
Mar 13, 2025Bernstein$259.00$254.571.74%-17.89%
Feb 28, 2025JMP Securities$348.00$271.8028.04%10.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2025Morgan StanleyOverweightOverweighthold
Sep 18, 2025BarclaysOverweightinitialise
Apr 07, 2025RBC CapitalOutperforminitialise
Feb 28, 2025MacquarieOutperformOutperformhold
Feb 28, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-6.12--
Avg Forecast$-5.83$-0.02$5.53
High Forecast$-5.20$2.11$8.75
Low Forecast$-6.62$-3.52$0.75
Surprise %4.97%--

Revenue Forecast

$4B $4B $5B $6B $7B $8B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$3.81B--
Avg Forecast$3.77B$4.84B$5.98B
High Forecast$3.78B$4.96B$7.00B
Low Forecast$3.75B$4.71B$5.02B
Surprise %1.07%--

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 24 Dec 25 Dec 26
Dec 24Dec 25Dec 26
Reported$-644.79M--
Avg Forecast$-613.83M$-2.11M$582.26M
High Forecast$-547.50M$222.16M$921.72M
Low Forecast$-697.01M$-370.61M$78.97M
Surprise %5.04%--

ONC Forecast FAQ

Is BeOne Medicines stock a buy?

BeOne Medicines stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BeOne Medicines is a favorable investment for most analysts.

What is BeOne Medicines's price target?

BeOne Medicines's price target, set by 9 Wall Street analysts, averages $384 over the next 12 months. The price target range spans from $383 at the low end to $385 at the high end, suggesting a potential 21.74% change from the previous closing price of $315.43.

How does BeOne Medicines stock forecast compare to its benchmarks?

BeOne Medicines's stock forecast shows a 21.74% upside, outperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for BeOne Medicines over the past three months?

  • October 2025: 29.63% Strong Buy, 62.96% Buy, 3.70% Hold, 3.70% Sell, 0% Strong Sell.
  • September 2025: 26.92% Strong Buy, 65.38% Buy, 3.85% Hold, 3.85% Sell, 0% Strong Sell.
  • August 2025: 30.43% Strong Buy, 65.22% Buy, 4.35% Hold, 0% Sell, 0% Strong Sell.

What is BeOne Medicines’s EPS forecast?

BeOne Medicines's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.02, marking a -99.67% decrease from the reported $-6.12 in 2024. Estimates for the following years are.

What is BeOne Medicines’s revenue forecast?

BeOne Medicines's average annual revenue forecast for its fiscal year ending in December 2025 is $4.84B, reflecting a 27.03% increase from the reported $3.81B in 2024. The forecast for.

What is BeOne Medicines’s net income forecast?

BeOne Medicines's net income forecast for the fiscal year ending in December 2025 stands at $-2.106M, representing a -99.67% decrease from the reported $-645M in 2024. Projections indicate .